We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Federal Trade Commission took CellMark Biopharma to federal court for falsely advertising two of its supplements as “clinically proven” to treat cancer and cancer treatment side effects. Read More
A new CDER-funded study says the FDA is not taking full advantage of social media to communicate drug safety information — and should, for example, be making more use of Twitter in its campaigns. Read More
The FDA will prioritize the opioid crisis, innovation, and generic competition in the coming year, the agency said in a 2018 Strategic Policy Roadmap released Thursday. Read More
CDER achieved numerous firsts in its past year of drug approvals, covering treatments for several rare diseases, cancer therapies and antibiotics. Read More
The House Energy and Commerce Committee released a review of the 340B drug discount pricing program, identifying weaknesses in oversight and administration, among other issues, and offering recommendations to resolve them. Read More